There are currently 302 clinical trials in Fort Worth, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Cook Children's Medical Center, GSK Investigational Site, Cook Children's Medical Center - Fort Worth and UT Southwestern/Simmons Cancer Center-Fort Worth. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility
NCT01354002
Recruiting
The aims of this protocol are: to collect and store diseased and normal tissue and body fluid samples from new and returning patients at St. Jude Children's Research Hospital (SJCRH), affiliated sites and collaborating institutions; to collect and store samples from relatives of SJCRH patients; to collect and store retrospective and prospective pertinent corresponding clinical and laboratory data on disease characterization, treatment, and outcome; and to serve as a source of human biological sa... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/05/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Normal and Diseased Tissue and Body Fluids Samples
Register for Updates
Abbott Medical - VERITAS Study
NCT06707688
Recruiting
The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Baylor All Saints Medical Center at Fort Worth, Fort Worth, Texas
Conditions: Atrial Fibrillation (AF), Stoke
Register for Updates
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125
Recruiting
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/05/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Dravet Syndrome
Register for Updates
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
NCT06828861
Recruiting
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The main questions it aims to answer are: * Does ARD-101 improve the total score of the HQCT-9 (hyperphagia questionnaire for clinical trials, 9 questions)? * What medical problems do participants have when taking ARD-101? Researchers will compare ARD-101 to a placebo (a look-alike substance that con... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
08/04/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Hyperphagia, Prader-Willi Syndrome
Register for Updates
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
NCT05485961
Recruiting
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: 84000458 - Fort Worth Renal Group, Fort Worth, Texas
Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
Register for Updates
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080
Recruiting
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/01/2025
Locations: Texas Oncology, Fort Worth, Texas
Conditions: Large B-Cell Lymphoma
Register for Updates
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
NCT03339128
Recruiting
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D. Enrollment of 12-17 years old age group is closed, enrollment of the 6-11 years old age group will continue.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/01/2025
Locations: Cook Children's Med. Center /ID# 237537, Fort Worth, Texas
Conditions: Irritable Bowel Syndrome
Register for Updates
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429
Recruiting
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Texas Oncology - Fort Worth, Fort Worth, Texas
Conditions: Metastatic HER2-positive Breast Cancer
Register for Updates
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556
Recruiting
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: JPS Health Network, Fort Worth, Texas
Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Register for Updates
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas
Conditions: Stage III Colon Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239
Recruiting
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: JPS Health Network, Fort Worth, Texas
Conditions: Metastatic Breast Cancer
Register for Updates
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976
Recruiting
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Local Institution - 0337, Fort Worth, Texas
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates